DeutschNewstral
Article
Mmarketwatch.com on 2015-11-02 16:26
Citron Research urges media to take up baton on Valeant
Related news
- FValeant urges SEC to probe Citron claimsft.com
Citron scales back attack on Valeant, won’t release further allegationsThe Globe and Mail- Video: Valeant CEO: Sensational claims by Citron are completely untrueThe Globe and Mail
Citron Research’s Andrew Left: Meet the short seller behind those negative reports on Valeant Pharmaceuticals Incbusiness.financialpost.com- Andrew Left of Citron Research on why he’s questioning ShopifyThe Globe and Mail
- MMobileye shares slide after Citron Research cuts price targetmarketwatch.com
- MAnalyst refutes ‘flawed’ Citron Research report on Exact Sciencesmarketwatch.com
- MMallinckrodt stock drops 8% on new Citron Research reportmarketwatch.com
- BlackBerry jumps after Citron Research cites ‘game changer’ techThe Globe and Mail
- ICitron Research suggests GameStop should buy Esports Entertainmentinvezz.com
Mallinckrodt CEO fights back against Citron Research claimsbizjournals.com
Valeant Plunges 30% After Short Seller Citron Research Makes Fraud AllegationForbes- Citron Research Says S&P 500 Top Performer Nvidia Has Run Too Far In 2016Forbes
- Shopify shares fall 8 per cent after Citron Research questions business modelThe Globe and Mail
- MPeloton shares could be headed to $5, short-seller Citron Research saysmarketwatch.com
- HShort-seller Citron Research steps up its attack on TransDigm Group Inc.home.crainscleveland.com
- Who is Citron Research?The Globe and Mail
- MUPDATE: Exact Sciences Corp. stock drops 3% after short-seller Citron Research targets its colon cancer testmarketwatch.com
- MMallinckrodt’s stock tumbles as short seller Citron claims next victimmarketwatch.com
- Video: Valeant asks SEC to investigate Citron allegationsThe Globe and Mail